These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32938221)

  • 1. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma.
    Blomstergren A; Rydelius A; Abul-Kasim K; Lätt J; Sundgren PC; Bengzon J
    Acta Radiol; 2019 Apr; 60(4):516-525. PubMed ID: 29966430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
    Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
    Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
    Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
    J Neurosurg; 2019 Aug; 131(2):489-499. PubMed ID: 30485180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
    Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
    World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
    Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
    Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.
    Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z
    Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
    Harat M; Małkowski B; Roszkowski K
    Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.
    Zhang Z; Jiang H; Chen X; Bai J; Cui Y; Ren X; Chen X; Wang J; Zeng W; Lin S
    J Neurooncol; 2014 Aug; 119(1):207-14. PubMed ID: 24828264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.